新闻中心
- 296月
2026礼邦医药（09637.HK）正式在香港联合交易所主板挂牌上市 - 096月
2026Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long- Acting Anti-TSLP Antibody WIN378 - 086月
2026全球首个｜原启生物GPC3 CAR-T产品获NMPA批准开展II期确证性临床试验 - 086月
2026China NMPA Grants IND Clearance to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer - 046月
2026Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - 016月
2026Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement - 295月
2026Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - 285月
2026Avenzo Therapeutics Announces First Patient Dosed in Combination Cohort Evaluating CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) In Ongoing Phase 1/2 ORION-1 Study - 285月
2026Zenas BioPharma Anounces Submision of Biologics License Aplication (BLA) to U.S. FDA for Obexelimab in IgG4-RD FDA for Obexelimab in IgG4-RD - 185月
2026Design Therapeutics Announces Four-Week IV Data from the RESTORE-FA Trial of DT-216P2 Demonstrating Clinical Improvements and Comprehensive Biomarker Activity in Friedreich Ataxia - 065月
2026礼邦医药宣布 AP301 全球 III 期关键性多区域临床试验完成全部患者入组 - 055月
2026Sail Biomedicines Appoints Gene Marcantonio, M.D., Ph.D., as Chief Medical Officer - 045月
2026Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long- Acting Immunology Therapies With Best-in-Disease Potential - 045月
2026NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers - 284月
2026Avenzo Therapeutics Advances the Combination of CDK4 Selective Inhibitor (AVZO-023) with CDK2 Selective Inhibitor (AVZO-021) in Ongoing Phase 1/2 ORION-1 Study in HR+/HER2- Breast Cancer - 224月
2026Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - 144月
2026Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - 104月
2026原启生物宣布累计完成1.1 亿美元Pre-IPO 轮融资，加速实体肿瘤CAR-T 全 球开发进程 - 074月
2026NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer - 273月
2026Zenas BioPharma Anounces Pricing of Concurent Public Oferings of 2.50% Convertible Senior Notes Due 2032 and Comon Stock with Agregate Gros Proceds of $30.0 Milion Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million - 233月
2026Tempest Therapeutics Announces Up To $6 Million Private Placement - 183月
2026礼邦医药宣布与 R1 Therapeutics 达成 AP306 股权及海外授权合作协议 - 113月
2026Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - 232月
2026Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel - 112月
2026Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - 092月
2026Zenas BioPharma Anounces Late-Breaking Platform Presentation of Results from Phase 2 MonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - 121月
2026原启生物宣布首关7000 万美元C 轮融资，加速实体肿瘤CAR-T 全球开发进程 - 051月
2026Zenas BioPharma Anounces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Imunoglobulin G4-Related Disease (IgG4-RD) Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) - 2612月
2025Adicet Bio Announces Reverse Stock Split - 2112月
2025Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13 - 1512月
2025Zenas BioPharma's Partner, InoCare Pharma, Anounces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - 2611月
2025Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules - 2411月
2025Avenzo Therapeutics Granted Fast Track Designation for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with Urothelial Cancer Previously Treated with Enfortumab Vedotin - 1911月
2025Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer - 1711月
2025NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - 2310月
2025Sail Biomedicines Appoints Martin Mackay, Ph.D., to Its Board of Directors - 1610月
2025NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - 1610月
2025Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment- Refractory Rheumatoid Arthritis (RA) - 0810月
2025Zenas BioPharmand InoCare Pharma Anounce License Agrement Granting Zenas Rights for Thre Autoimune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis - 0710月
2025Adicet Bio, Inc. Announces $80 Million Registered Direct Offering
…